BetterLife Pharma Inc.

As of April 30, 2026, BetterLife Pharma Inc. carries a market capitalization of 9.71M, placing it among publicly traded companies globally. Its enterprise value stands at 14.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, BetterLife Pharma Inc. has 161.79M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, BetterLife Pharma Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.11, indicating conservative leverage, while an interest coverage ratio of -10.19 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -798.37, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BetterLife Pharma Inc.'s stock has gained approximately 291.67% over the past 52 weeks. The 50-day moving average sits at 0.28, while the 200-day moving average is 0.14.

Over the twelve months ended April 30, 2026, BetterLife Pharma Inc. generated - - in revenue and converted that into -1.89M in net income, yielding earnings per share of -0.01. EBITDA reached -1.88M, while operating income came in at -1.90M.

As of April 30, 2026, BetterLife Pharma Inc. holds 28,576.00 in cash and equivalents against 1.04M in total debt, resulting in a net debt position of 588,934.00. Total book value stands at -9.73M, with working capital of -6.41M providing operational flexibility.

BetterLife Pharma Inc. produced -850,443.00 in operating cash flow over the twelve months ended April 30, 2026.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -9.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.85, meaning BetterLife Pharma Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BetterLife Pharma Inc.'s most recent stock split took place on July 2, 2020 with a 10:1 split ratio.

As of April 30, 2026, BetterLife Pharma Inc. has an Altman Z-Score of -753.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.